NutriBand Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NutriBand Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $2.14M | Apr 28, 2025 |
| FY2025 | Jan 31, 2024 | $2.09M | Apr 28, 2025 |
| FY2024 | Jan 31, 2023 | $2.08M | May 1, 2024 |
| FY2023 | Jan 31, 2022 | $1.42M | Apr 26, 2023 |
| FY2022 | Jan 31, 2021 | $943.7K | Apr 29, 2022 |
| FY2021 | Jan 31, 2020 | $370.6K | Apr 2, 2021 |
| FY2020 | Jan 31, 2019 | $245.3K | Apr 14, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $743.3K | Apr 28, 2025 |
| FY2025 | Jan 31, 2024 | $862.1K | Apr 28, 2025 |
| FY2023 | Jan 31, 2023 | $750.4K | Apr 26, 2023 |
| FY2023 | Jan 31, 2022 | $554.3K | Apr 26, 2023 |
| FY2022 | Jan 31, 2021 | $316.2K | Apr 29, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | ($10.48M) | Apr 28, 2025 |
| FY2025 | Jan 31, 2024 | ($5.49M) | Apr 28, 2025 |
| FY2024 | Jan 31, 2023 | ($4.48M) | May 1, 2024 |
| FY2023 | Jan 31, 2022 | ($6.18M) | Apr 26, 2023 |
| FY2022 | Jan 31, 2021 | ($2.93M) | Apr 29, 2022 |
| FY2021 | Jan 31, 2020 | ($2.72M) | Apr 2, 2021 |
| FY2020 | Jan 31, 2019 | ($3.33M) | Apr 14, 2020 |
| FY2019 | Jan 31, 2018 | ($2.67M) | Apr 19, 2019 |
| FY2018 | Jan 31, 2017 | ($151.3K) | May 1, 2018 |
| FY2017 | Jan 31, 2016 | ($400) | May 8, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | ($10.28M) | Apr 28, 2025 |
| FY2025 | Jan 31, 2024 | ($4.87M) | Apr 28, 2025 |
| FY2024 | Jan 31, 2023 | ($4.48M) | May 1, 2024 |
| FY2023 | Jan 31, 2022 | ($6.11M) | Apr 26, 2023 |
| FY2022 | Jan 31, 2021 | ($2.60M) | Apr 29, 2022 |
| FY2021 | Jan 31, 2020 | ($1.97M) | Apr 2, 2021 |
| FY2020 | Jan 31, 2019 | ($3.33M) | Apr 14, 2020 |
| FY2018 | Jan 31, 2018 | ($2.67M) | May 1, 2018 |
| FY2018 | Jan 31, 2017 | ($151.3K) | May 1, 2018 |
| FY2017 | Jan 31, 2016 | ($400) | May 8, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $3.12M | Apr 28, 2025 |
| FY2025 | Jan 31, 2024 | $1.96M | Apr 28, 2025 |
| FY2024 | Jan 31, 2023 | $982.2K | May 1, 2024 |
| FY2023 | Jan 31, 2022 | $411.4K | Apr 26, 2023 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $4.31M | Apr 28, 2025 |
| FY2025 | Jan 31, 2024 | $3.77M | Apr 28, 2025 |
| FY2024 | Jan 31, 2023 | $3.92M | May 1, 2024 |
| FY2023 | Jan 31, 2022 | $4.02M | Apr 26, 2023 |
| FY2022 | Jan 31, 2021 | $2.91M | Apr 29, 2022 |
| FY2021 | Jan 31, 2020 | $1.79M | Apr 2, 2021 |
| FY2020 | Jan 31, 2019 | $3.29M | Apr 14, 2020 |
| FY2019 | Jan 31, 2018 | $171.9K | Apr 19, 2019 |
| FY2018 | Jan 31, 2017 | $151.3K | May 1, 2018 |
| FY2017 | Jan 31, 2016 | $400 | May 8, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | ($4.63M) | Apr 28, 2025 |
| FY2025 | Jan 31, 2024 | ($3.53M) | Apr 28, 2025 |
| FY2024 | Jan 31, 2023 | ($2.99M) | May 1, 2024 |
| FY2023 | Jan 31, 2022 | ($2.81M) | Apr 26, 2023 |
| FY2022 | Jan 31, 2021 | ($297.1K) | Apr 29, 2022 |
| FY2021 | Jan 31, 2020 | ($894.5K) | Apr 2, 2021 |
| FY2020 | Jan 31, 2019 | ($1.11M) | Apr 14, 2020 |
| FY2019 | Jan 31, 2018 | ($92.9K) | Apr 19, 2019 |
| FY2018 | Jan 31, 2017 | ($147.9K) | May 1, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $92.0K | Apr 28, 2025 |
| FY2025 | Jan 31, 2024 | $51.8K | Apr 28, 2025 |
| FY2024 | Jan 31, 2023 | $79.3K | May 1, 2024 |
| FY2023 | Jan 31, 2022 | $81.6K | Apr 26, 2023 |
| FY2019 | Jan 31, 2019 | $4.2K | Apr 19, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $7.47M | Apr 28, 2025 |
| FY2025 | Jan 31, 2024 | $7.52M | Apr 28, 2025 |
| FY2024 | Jan 31, 2023 | $9.46M | May 1, 2024 |
| FY2023 | Jan 31, 2022 | $12.74M | Apr 26, 2023 |
| FY2022 | Jan 31, 2021 | $9.93M | Apr 29, 2022 |
| FY2021 | Jan 31, 2020 | $2.20M | Apr 2, 2021 |
| FY2020 | Jan 31, 2019 | $2.81M | Apr 14, 2020 |
| FY2019 | Jan 31, 2018 | $164.9K | Apr 19, 2019 |
| FY2018 | Jan 31, 2017 | $37.7K | May 1, 2018 |
| FY2017 | Jan 31, 2016 | $330 | May 8, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $1.04M | Apr 28, 2025 |
| FY2025 | Jan 31, 2024 | $1.08M | Apr 28, 2025 |
| FY2024 | Jan 31, 2023 | $883.4K | May 1, 2024 |
| FY2023 | Jan 31, 2022 | $880.4K | Apr 26, 2023 |
| FY2022 | Jan 31, 2021 | $2.82M | Apr 29, 2022 |
| FY2021 | Jan 31, 2020 | $2.02M | Apr 2, 2021 |
| FY2017 | Jan 31, 2017 | $14.6K | May 8, 2017 |
| FY2017 | Jan 31, 2016 | $11.8K | May 8, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $6.43M | Apr 28, 2025 |
| FY2025 | Jan 31, 2024 | $6.44M | Apr 28, 2025 |
| FY2025 | Jan 31, 2023 | $8.57M | Apr 28, 2025 |
| FY2024 | Jan 31, 2022 | $11.86M | May 1, 2024 |
| FY2023 | Jan 31, 2021 | $7.11M | Apr 26, 2023 |
| FY2022 | Jan 31, 2020 | $175.4K | Apr 29, 2022 |
| FY2021 | Jan 31, 2019 | $2.40M | Apr 2, 2021 |
| FY2020 | Jan 31, 2018 | $121.5K | Apr 14, 2020 |
| FY2019 | Jan 31, 2017 | $23.1K | Apr 19, 2019 |
| FY2018 | Jan 31, 2016 | ($11.5K) | May 1, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $1.72M | Apr 28, 2025 |
| FY2025 | Jan 31, 2024 | $5.02M | Apr 28, 2025 |
| FY2024 | Jan 31, 2023 | $5.02M | May 1, 2024 |
| FY2023 | Jan 31, 2022 | $5.35M | Apr 26, 2023 |
| FY2022 | Jan 31, 2021 | $7.53M | Apr 29, 2022 |
| FY2021 | Aug 31, 2020 | $5.81M | Apr 2, 2021 |
| FY2021 | Jan 31, 2020 | $1.72M | Apr 2, 2021 |
| FY2020 | Jan 31, 2019 | $1.72M | Apr 14, 2020 |
| FY2019 | Aug 2, 2018 | $1.72M | Apr 19, 2019 |
| FY2020 | Aug 1, 2018 | $1.72M | Apr 14, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | ($38.46M) | Apr 28, 2025 |
| FY2025 | Jan 31, 2024 | ($27.98M) | Apr 28, 2025 |
| FY2024 | Jan 31, 2023 | ($22.49M) | May 1, 2024 |
| FY2023 | Jan 31, 2022 | ($18.01M) | Apr 26, 2023 |
| FY2022 | Jan 31, 2021 | ($11.84M) | Apr 29, 2022 |
| FY2021 | Jan 31, 2020 | ($8.90M) | Apr 2, 2021 |
| FY2020 | Jan 31, 2019 | ($6.18M) | Apr 14, 2020 |
| FY2019 | Jan 31, 2018 | ($2.85M) | Apr 19, 2019 |
| FY2018 | Jan 31, 2017 | ($177.5K) | May 1, 2018 |
| FY2017 | Jan 31, 2016 | ($26.2K) | May 8, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $4.31M | Apr 28, 2025 |
| FY2025 | Jan 31, 2024 | $492.9K | Apr 28, 2025 |
| FY2024 | Jan 31, 2023 | $1.99M | May 1, 2024 |
| FY2023 | Jan 31, 2022 | $4.89M | Apr 26, 2023 |
| FY2022 | Jan 31, 2021 | $152.0K | Apr 29, 2022 |
| FY2021 | Jan 31, 2020 | $10.2K | Apr 2, 2021 |
| FY2021 | Jan 31, 2019 | $474.7K | Apr 2, 2021 |
| FY2019 | Jan 31, 2017 | $27.1K | Apr 19, 2019 |
| FY2018 | Oct 31, 2016 | $6.2K | May 1, 2018 |
| FY2018 | Jan 31, 2016 | $100 | May 1, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Jan 31, 2018 | $1.8K | May 1, 2018 |
| FY2018 | Jan 31, 2017 | $1.6K | May 1, 2018 |
| FY2017 | Jan 31, 2016 | $1.6K | May 8, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | 0 | Apr 28, 2025 |
| FY2025 | Jan 31, 2024 | 0 | Apr 28, 2025 |
| FY2024 | Jan 31, 2023 | 0 | May 1, 2024 |
| FY2023 | Jan 31, 2022 | 0 | Apr 26, 2023 |
| FY2022 | Jan 31, 2021 | 0 | Apr 29, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | 0 | Apr 28, 2025 |
| FY2025 | Jan 31, 2024 | 0 | Apr 28, 2025 |
| FY2024 | Jan 31, 2023 | 0 | May 1, 2024 |
| FY2023 | Jan 31, 2022 | 0 | Apr 26, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | 11.07M | Apr 28, 2025 |
| FY2025 | Jan 31, 2024 | 8.86M | Apr 28, 2025 |
| FY2024 | Jan 31, 2023 | 7.83M | May 1, 2024 |
| FY2023 | Jan 31, 2022 | 9.15M | Apr 26, 2023 |
| FY2022 | Jan 31, 2021 | 6.26M | Apr 29, 2022 |
| FY2021 | Jan 31, 2020 | 5.44M | Apr 2, 2021 |
| FY2020 | Jan 31, 2019 | 5.42M | Apr 14, 2020 |
| FY2019 | Jan 31, 2018 | 20.88M | Apr 19, 2019 |
| FY2018 | Jan 31, 2017 | 15.57M | May 1, 2018 |
| FY2017 | Jan 31, 2016 | 21.88M | May 8, 2017 |